Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This extension study is designed to assess the long term safety and efficacy of zoledronic
acid in postmenopausal women with osteoporosis who have participated in the CZOL446H2301
(NCT00049829): HORIZON Pivotal Fracture Trial. This extension study began after the 3-year
core study ended. Baseline is the same as Year 3.